{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:23:52Z","timestamp":1761513832579,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clbc.2020.01.006","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T20:08:27Z","timestamp":1580155707000},"page":"e397-e402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ"],"prefix":"10.1016","volume":"20","author":[{"given":"Bradley C.","family":"Bandera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Voci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Barrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevan D.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie L.","family":"DiNome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Ries","key":"10.1016\/j.clbc.2020.01.006_bib1"},{"key":"10.1016\/j.clbc.2020.01.006_bib2","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1200\/JCO.2005.04.038","article-title":"Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of Surveillance, Epidemiology, and End Results data","volume":"23","author":"Chuba","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-012-2318-8","article-title":"The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions","volume":"136","author":"Coopey","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.01.006_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.clbc.2020.01.006_bib5","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast cancer prevention in post-menopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2020.01.006_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.01.006_bib7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial","volume":"383","author":"Cusick","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2020.01.006_bib8","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","article-title":"Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk","volume":"33","author":"King","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib10","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/tbj.12418","article-title":"Breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ","volume":"21","author":"Reimers","year":"2015","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2020.01.006_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib13","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1940-6207.CAPR-17-0100","article-title":"Chemoprevention uptake among women with atypical hyperplasia and lobular and ductal carcinoma in situ","volume":"10","author":"Trivedi","year":"2017","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.clbc.2020.01.006_bib15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1245\/s10434-019-07236-8","article-title":"Chemoprevention uptake for breast cancer risk reduction varies by risk factor","volume":"26","author":"Flanagan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.20205","article-title":"Acceptance of tamoxifen chemoprevention by physicians and women at risk","volume":"100","author":"Tchou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.01.006_bib17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/bjc.2014.109","article-title":"Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic","volume":"110","author":"Donnelly","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.01.006_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib19","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1200\/JCO.2004.05.192","article-title":"Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors","volume":"22","author":"Bober","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1006\/pmed.1998.0349","article-title":"The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial","volume":"27","author":"Kinney","year":"1998","journal-title":"Prev Med"},{"key":"10.1016\/j.clbc.2020.01.006_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cncr.11051","article-title":"Racial\/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35","volume":"97","author":"Shavers","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.01.006_bib22","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv202","article-title":"Impact of fertility concerns on tamoxifen initiation and persistence","volume":"107","author":"Llarena","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.01.006_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdf039","article-title":"Very young women (<35 years) with operable breast cancer: features of disease at presentation","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.01.006_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/PAS.0b013e318161d1a5","article-title":"Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family","volume":"32","author":"Abdel-Fateh","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2020.01.006_bib26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.amjsurg.2008.06.017","article-title":"Regional variation in breast cancer treatment throughout the United States","volume":"196","author":"Sariego","year":"2008","journal-title":"Am J Surg"},{"key":"10.1016\/j.clbc.2020.01.006_bib27","first-page":"976","article-title":"Traveling towards disease: transportation barriers to health care access","volume":"38","author":"Syed","year":"2013","journal-title":"J\u00a0Community Health"},{"key":"10.1016\/j.clbc.2020.01.006_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tbj.12999","article-title":"Variations in cancer care for adolescents and young adults (AYAs) with ductal carcinoma in situ","volume":"24","author":"Voci","year":"2018","journal-title":"Breast J"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920300227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920300227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:20:40Z","timestamp":1761513640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820920300227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1526820920300227"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2020.01.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2020.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}